Details for New Drug Application (NDA): 208129
✉ Email this page to a colleague
The generic ingredient in DEXMEDETOMIDINE HYDROCHLORIDE is dexmedetomidine hydrochloride. There are fourteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the dexmedetomidine hydrochloride profile page.
Summary for 208129
| Tradename: | DEXMEDETOMIDINE HYDROCHLORIDE |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | dexmedetomidine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 208129
| Mechanism of Action | Adrenergic alpha2-Agonists |
| Physiological Effect | General Anesthesia |
Medical Subject Heading (MeSH) Categories for 208129
Suppliers and Packaging for NDA: 208129
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 208129 | ANDA | Fresenius Kabi USA, LLC | 63323-671 | 63323-671-00 | 10 BOTTLE, GLASS in 1 CARTON (63323-671-00) / 100 mL in 1 BOTTLE, GLASS (63323-671-01) |
| DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 208129 | ANDA | Fresenius Kabi USA, LLC | 63323-671 | 63323-671-20 | 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-671-20) / 20 mL in 1 VIAL, SINGLE-DOSE (63323-671-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | ||||
| Approval Date: | Nov 29, 2018 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | ||||
| Approval Date: | Nov 29, 2018 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | ||||
| Approval Date: | Nov 29, 2018 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
